Table 2

Preplanned subgroup analysis

ParameterComparisonsPatients/control subjectsEstimate (95% CI)P valueI2P value of Q test
WMD
HbA1c (%)
 All comparisons305,689/5,736−0.47 (−0.59, −0.35)<0.00193.7<0.001
 GLP-1RA/Ins vs.
  Placebo/intensification131,720/1,536−0.68 (−0.86, −0.50)<0.00188.8<0.001
  Placebo101,631/1,454−0.76 (−0.96, −0.57)<0.00189.0<0.0001
  Intensification389/82−0.37 (−0.70, −0.04)0.02975.90.016
  B-B/B-P91,653/1,654−0.11 (−0.20, −0.01)0.03169.60.001
  B-B71,416/1,267−0.08 (−0.19, 0.04)0.17770.70.002
  B-P2237/387−0.20 (−0.40, 0.01)0.05768.30.076
 FC vs. intensification82,316/2,546−0.56 (−0.72, −0.40)<0.00192.0<0.001
 IDegLira41,319/1,314−0.68 (−0.87, −0.48)<0.00184.9<0.001
 IGlarLixi4997/1,232−0.44 (−0.70, −0.19)<0.00194.9<0.001
 Short-acting GLP-1RAs132,535/2,890−0.32 (−0.49, −0.15)<0.00194.4<0.001
 Long-acting GLP-1RAs173,154/2,846−0.60 (−0.75, −0.44)<0.00190.7<0.001
RR
HbA1c ≤7%
 All comparisons285,607/5,6561.65 (1.44, 1.88)<0.00191.1<0.001
 GLP-1RA/Ins vs.
  Placebo/intensification131,720/1,5362.67 (1.89, 3.79)<0.00189.7<0.001
  Placebo101,631/1,4543.16 (2.20, 4.54)<0.00187.9<0.001
  Intensification389/821.43 (0.72, 2.83)0.30375.60.017
  B-B/B-P71,571/1,5741.09 (0.99, 1.20)0.07628.80.209
  B-B51,334/1,1871.07 (0.95, 1.20)0.08541.90.142
  B-P2237/3871.18 (0.98, 1.41)0.2720.00.419
 FC vs. intensification82,316/2,5461.54 (1.30, 1.81)<0.00192.8<0.001
 IDegLira41,319/1,3141.55 (1.27, 1.89)<0.00190.3<0.001
 IGlarLixi4997/1,2321.52 (1.09, 2.12)0.01395.6<0.001
 Short-acting GLP-1RAs112,453/2,8101.49 (1.22, 1.83)<0.00191.9<0.001
 Long-acting GLP-1RAs173,154/2,8461.80 (1.49, 2.17)<0.00190.8<0.001
Hypoglycemia
 All comparisons254,928/5,2751.14 (0.93, 1.39)0.21489.3<0.001
 GLP-1RA/Ins vs.
  Placebo/intensification111,635/1,4601.41 (1.11, 1.80)0.00668.00.001
  Placebo91,567/1,3941.47 (1.16, 1.88)0.00267.10.002
  Intensification268/660.85 (0.19, 3.82)0.82985.60.008
  B-B/B-P6977/1,2690.68 (0.52, 0.89)0.00578.6<0.001
  B-B5828/9710.66 (0.46, 0.93)0.01883.2<0.001
  B-P1149/2980.76 (0.60, 0.98)0.032
 FC vs. intensification82,316/2,5461.26 (0.85, 1.87)0.25394.2<0.001
 IDegLira41,319/1,3141.19 (0.57, 2.46)0.64396.7<0.001
 IGlarLixi4997/1,2321.33 (0.84, 2.12)0.22688.8<0.001
 Short-acting GLP-1RAs132,535/2,8901.05 (0.82, 1.34)0.69786.6<0.001
 Long-acting GLP-1RAs122,393/2,3851.27 (0.89, 1.82)0.19291.9<0.001
WMD
Weight (kg)
 All comparisons274,927/5,268−2.5 (−3.3, −1.7)<0.00197.3<0.001
 GLP-1RA/Ins vs.
  Placebo/intensification121,546/1,364−2.6 (−3.8, −1.5)<0.00196.3<0.001
  Placebo91,457/1,282−1.5 (−2.3, −0.6)<0.00192.5<0.001
  Intensification389/82−6.3 (−8.0, −4.6)<0.00173.80.022
  B-B/B-P71,065/1,358−4.1 (−5.7, −2.5)<0.00196.4<0.001
  B-B5828/971−4.7 (−6.9, −2.4)<0.00197.3<0.001
  B-P2237/387−2.7 (−4.7, −0.7)0.00891.10.001
 FC vs. Intensification82,316/2,546−1.0 (−2.4, 0.5)0.18198.1<0.001
 IDegLira41,319/1,314−1.4 (−4.1, 1.3)0.32399.0<0.001
 IGlarLixi4997/1,232−0.6 (−2.1, 0.9)0.45596.1<0.001
 Short-acting GLP-1RAs132,535/2,890−2.3 (−3.3, −1.3)<0.00196.7<0.001
 Long-acting GLP-1RAs142,392/2,378−2.7 (−4.0, −1.3)<0.00197.8<0.001
  • B-B, basal-bolus; B-P, basal-plus; FC, fixed-ratio combination; GLP-1RA/Ins, GLP-1RA plus insulin.